ZIOPHARM Oncology Inc (ZIOP) Receives Average Recommendation of “Hold” from Analysts
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has been given an average rating of “Hold” by the six research firms that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $12.50.
ZIOP has been the topic of a number of research analyst reports. Zacks Investment Research raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, April 26th. HC Wainwright assumed coverage on ZIOPHARM Oncology in a report on Thursday, June 1st. They set a “buy” rating and a $9.50 target price on the stock.
ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/17/ziopharm-oncology-inc-ziop-receives-average-recommendation-of-hold-from-analysts.html.
Shares of ZIOPHARM Oncology (NASDAQ ZIOP) opened at 5.87 on Monday. ZIOPHARM Oncology has a 12 month low of $4.45 and a 12 month high of $7.88. The firm’s 50 day moving average is $6.27 and its 200 day moving average is $6.33. The stock’s market capitalization is $767.21 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings results on Monday, May 1st. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.03. The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.71 million. The company’s revenue for the quarter was down 18.8% compared to the same quarter last year. On average, equities analysts predict that ZIOPHARM Oncology will post ($0.58) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mission Wealth Management LLC purchased a new position in ZIOPHARM Oncology during the first quarter worth about $108,000. Highbridge Capital Management LLC purchased a new position in ZIOPHARM Oncology during the fourth quarter worth about $164,000. Old West Investment Management LLC purchased a new position in ZIOPHARM Oncology during the first quarter worth about $205,000. UBS Asset Management Americas Inc. raised its position in ZIOPHARM Oncology by 79.6% in the first quarter. UBS Asset Management Americas Inc. now owns 37,687 shares of the biotechnology company’s stock worth $239,000 after buying an additional 16,700 shares during the last quarter. Finally, Private Advisor Group LLC raised its position in ZIOPHARM Oncology by 23.4% in the first quarter. Private Advisor Group LLC now owns 41,541 shares of the biotechnology company’s stock worth $260,000 after buying an additional 7,875 shares during the last quarter. 38.06% of the stock is currently owned by hedge funds and other institutional investors.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.